PlumX Metrics
Embed PlumX Metrics

Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: A review

Medical Oncology, ISSN: 1357-0560, Vol: 29, Issue: 2, Page: 776-785
2012
  • 12
    Citations
  • 0
    Usage
  • 470
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Review Description

The results of cytotoxic therapy in the secondline setting of metastatic castration-resistant prostate cancer have demonstrated that disease is poorly controlled after taxane resistance with a time to progression of 3 months or less. Many trials of second-line chemotherapy have been disappointing. However, most of patients with docetaxel-pretreated castration-resistant disease receive a second-line chemotherapy. Molecular mechanism of castration resistance and docetaxel resistance is resumed, and clinical trials of second-line chemotherapy after docetaxel progression are reviewed. Reintroduction of docetaxel after a drug-free interval is an active treatment in docetaxelpretreated patients, and only recently a prospective study documented a survival benefit of 2.4 months after second-line taxane-based chemotherapy of metastatic docetaxel-resistant prostate cancer. Although a second-line chemotherapy with a taxane could improve overall survival, a change of biology of castration-resistant prostate cancer after docetaxel is suggested, as inferred by the renewed hormonal sensitivity, whose role on survival remains unknown, and from the activity of antiangiogenic drugs. © Springer Science+Business Media, LLC 2011.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know